Fortress Biotech Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
2analysts covering
FY Revenue (est.)
$79.9Mnext fiscal year
FY EPS (est.)
$2.40next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 12 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Consolidated Net Revenue Quarterly16M
Journey Medical Net Product Revenue Quarterly15.9MTarget: Sustained double-digit growth
Consolidated Cash and Cash Equivalents Quarterly255.8MTarget: Maintain strong liquidity post-PRV monetization
Watch Items
- Commercial launch and royalty ramp of UNLOXCYT (cosibelimab-ipdl) by Sun PharmaTrigger: Royalty rate of 2.5% on net salesAction: Monitor quarterly royalty statements and Sun Pharma commercial updates
- Sentynl Therapeutics commercialization of ZYCUBO (copper histidinate)Trigger: Up to $129 million in aggregate development and sales milestones plus tiered royaltiesAction: Track clinical/regulatory progress and commercial sales reports from Sentynl
- AstraZeneca regulatory submissions for anselamimab (CAEL-101) in EU and JapanTrigger: Regulatory approval decisions in EU and JapanAction: Monitor partner pipeline announcements and regulatory filings
Research as of 19 Jun 2026